Rescue of a primary myelofibrosis model by retinoid-antagonist therapy - Wikidata - wikimedia - TriplyDB

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

http://www.wikidata.org/entity/Q30557756

about

NCoR1 and SMRT play unique roles in thyroid hormone action in vivo Efficacy of ALK5 inhibition in myelofibrosis.Short linear motif acquisition, exon formation and alternative splicing determine a pathway to diversity for NCoR-family co-repressors.Imaging Fibrosis and Separating Collagens using Second Harmonic Generation and Phasor Approach to Fluorescence Lifetime Imaging A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression.Genomic characterization of spleens in patients with myelofibrosis Bones in human CYP26B1 deficiency and rats with hypervitaminosis A phenocopy overexpression

P2860

Q34846614-9C81FA44-05EF-485C-93D6-D702C22EA32D Q37730812-CB472C88-AC7C-489D-8C3C-4A6E3DD36E55 Q40625890-77603810-E81D-4740-A714-D9CD27F98E80 Q42577388-9893537F-B2ED-4173-8FFB-7EFEF809BB59 Q55261210-08C98245-3315-49FB-9D31-50241969034F Q58793731-E3FA816F-4741-4F98-8D9F-382AF7AFB2C0 Q58831338-2A13EAA7-4914-4D6B-92E2-D2470355BC1E

P2860

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

http://www.wikidata.org/entity/Q30557756

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

@ast

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

@en

type

label

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

@ast

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

@en

prefLabel

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

@ast

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

@en

P1433

Q30557756-B8374F54-FAB8-4477-9152-6A299CD24F58

P1476

Q30557756-8E5E58BA-9A95-413E-8D92-ED6F62AC5D2B

P2093

Q30557756-0DADDA00-A381-4592-89C0-AAEE372D2045

Q30557756-1F5125E6-88B3-4F61-B76C-58214F8E17F1

Q30557756-33997DA1-0048-470D-9884-BBE925FD1540

Q30557756-38D16E0D-3E7B-4B67-82AE-D6D3983FDE2F

Q30557756-615EB179-3544-48CB-9B88-4757229D8F4A

Q30557756-7767A1E8-990C-4ABC-9980-75DC5D4AEC7E

Q30557756-79E3602E-520F-47D4-88D4-CCDFEB226FB5

Q30557756-F0490477-5CAF-4BE6-A5A0-E1D34E305E24

P2860

Q30557756-0A41F101-2F0C-4133-804F-3D0AC19216A6

Q30557756-0B6C68F7-00AB-40EC-8656-F06111247CFD

Q30557756-0B735BD4-8E52-4E9B-A17A-695F418B5092

Q30557756-101E5A26-981E-4DE9-BC2D-85FB17CC849A

Q30557756-12AB60CC-B058-4794-9E9B-E5251E3814E0

Q30557756-1A02AE81-392D-4920-9A17-460A882C8AC7

Q30557756-218A113F-66D6-47FD-B401-D97A45ECB208

Q30557756-43D35FDD-1D3D-46E5-84A1-B16C96674C67

Q30557756-5D103BDC-40FA-48C8-A826-75744851E999

Q30557756-66072579-0652-4954-8410-46B3DF4786D5

P304

Q30557756-3285B15C-9227-4204-BBC3-2648B72DCC10

P31

Q30557756-E9F0CF24-8585-4DE6-A542-30FCDE250EBB

P356

Q30557756-8F8225BD-78FD-4988-ACDA-707EE0D279F8

P407

Q30557756-02604C57-663B-4653-8890-D7494055759B

P433

Q30557756-BFCF1A52-905E-4E0B-AE8F-6DFE25DD77EE

P478

Q30557756-7415A093-6695-47D3-A535-8D3B2B72B081

P50

Q30557756-EA3DDC93-601B-4008-A608-01D61B6F39D2

P577

Q30557756-D446A1EF-8257-4D94-BAB6-BC72FC061CCD

P5875

Q30557756-C56CB4BB-1F00-4CA4-941E-5357F7D2BDA8

P698

Q30557756-24CC000F-774C-4AE1-9755-51D8DE93B619

P932

Q30557756-A67BB353-8EDA-4955-BA5F-F64E61A684F9

P356

PNAS.1318974110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Rescue of a primary myelofibrosis model by retinoid-antagonist therapy

@en

P2093

Dolores Shoback

http://www.w3.org/2001/XMLSchema#string

Glenda L Castro

http://www.w3.org/2001/XMLSchema#string

Grant D Barish

http://www.w3.org/2001/XMLSchema#string

Hazel Y Stevens

http://www.w3.org/2001/XMLSchema#string

John A Frangos

http://www.w3.org/2001/XMLSchema#string

Melita Dvorak-Ewell

http://www.w3.org/2001/XMLSchema#string

Russell Nofsinger

http://www.w3.org/2001/XMLSchema#string

Suk-Hyun Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor

SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis

Unique forms of human and mouse nuclear receptor corepressor SMRT

Bone resorption by osteoclasts

A transcriptional co-repressor that interacts with nuclear hormone receptors

Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.

Transcriptional silencing is defined by isoform- and heterodimer-specific interactions between nuclear hormone receptors and corepressors

Steroid hormone receptor expression and action in bone.

Some speculations on the myeloproliferative syndromes.

P304

18820-18825

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1318974110

http://www.w3.org/2001/XMLSchema#string

P407

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Ronald M. Evans

P577

2013-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258282562

http://www.w3.org/2001/XMLSchema#string

P698

24191050

http://www.w3.org/2001/XMLSchema#string

P932

3839709

http://www.w3.org/2001/XMLSchema#string